Efficacy and Safety of Concurrent Chemoradiotherapy with Docetaxel for Locally Advanced Breast Carcinoma after Modified Radical Mastectomy


Breast cancer
Modified radical mastectomy
Concurrent chemoradiotherapy


How to Cite

Wang, J., Wei, C., Liu, W. ., Wang, B., & Han, Q. (2022). Efficacy and Safety of Concurrent Chemoradiotherapy with Docetaxel for Locally Advanced Breast Carcinoma after Modified Radical Mastectomy. Iranian Red Crescent Medical Journal, 24(7). Retrieved from https://ircmj.com/index.php/IRCMJ/article/view/1992


Background: Breast cancer is a common term for a malignant tumor that arises from the epithelial component of the breast. Concurrent chemoradiotherapy’s efficacy and safety are controversial, considering the impact on patients' quality of life.
Objective: To investigate the efficacy and safety of concurrent chemoradiotherapy with docetaxel in locally advanced breast cancer who have received a modified radical mastectomy.
Methods: A cohort of 110 female patients with locally advanced breast cancer were included in the present study and divided by chemoradiotherapy mode into a concurrent chemoradiotherapy group (n=58) and a sequential chemoradiotherapy group (n=52). The two groups were compared with respect to clinical efficacy, levels of tumor markers across vascular endothelial growth factor (VEGF), and carcinoembryonic antigen (CEA).
Results: The overall response rate came at 45.83% in the concurrent group and 40.48% in the sequential group. There was no remarkable difference in VEGF and CEA levels between the two groups (P < 0.05); After treatment, the levels were significantly lower than those in the same group before treatment (P < 0.05). The median survival time was 26 months in the concurrent group and 25 months in the other group, while their 3-year survival rates varied greatly (79.17% for the concurrent VS 69.05% for the sequential) (P>0.05).
Conclusion: The chemotherapy protocol with a combination of cyclophosphamide, fluorouracil and epirubicin with concurrent docetaxel presented higher efficacy and prolonged the overall survival in locally advanced breast cancer patients who had undergone a radical mastectomy, while it did not significantly increase the toxicity.


Liu H., Li Y., Zhong L., et al. The research progress of circulating tumor DNA in breast cancer. Cancer Progress. 2019;17(10):1126–9.

Zhao Y., Wang J., Tang J., et al. Diagnostic criteria of vascular endothelial growth factor and microvessel density in breast cancer. J Vasc Endovasc Surg. 2018;4(5):68–72.

Group C breast cancer neoadjuvant therapy expert. Expert consensus on neoadjuvant therapy for breast cancer in China (2019 Edition). Chin J Cancer. 2019;29(5):390–400.

Sun L., Shen Z. New progress in diagnosis and treatment of elderly breast canceNo Title. Mod Oncol. 2016;24(22):3663–6.

Cheng Y., Ye H., Wang A., et al. Study on the effect of concurrent chemoradiotherapy and influencing factors of distant metastasis in advanced cervical squamous cell carcinoma. Hebei Med. 2016;38(19):2939–41.

Liu W., Li J., Wang T., et al. Efficacy and safety of anthracyclines combined with taxanes in neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2016;21(3):228–32.

Dong Y., Yang J., Xu M., et al. Analysis on death status and trend of female breast cancer in Wuxi City from 2009 to 2014. Pract Prev Med. 2017;24(1):12–4.

Hu Z., Yu Z. Investigation and analysis of radiotherapy after modified radical mastectomy in China. Chinese J Radiat Oncol. 2005;14(6):471–5.

Xuan L., Meng X., Sun B., et al. Clinical observation of docetaxel combined with bevacizumab in the treatment of multidrug-resistant breast cancer. Chinese J cancer Prev Treat. 2019;26(5):316–9.

Coudert B., Asselain B., Campone M., Spielmann M., Machiels J-P., Pénault-Llorca F., et al. Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial. Oncologist. 2012;17(7):900–9. doi:10.1634/theoncologist.2011-0442.

Zhang M., Luo F. Cardiovascular risk and Countermeasures of anthracyclines in the treatment of breast cancer. Cancer Res Clin. 2018;30(3):173–5.

Lei Y., Yan C., Xue Q., et al. Expression and clinical significance of VEGF and VEGFR in NSCLC. Cancer Progress. 2019;17(13):1573–5.

Zhang C., Jiang W. Expression and significance of serum lactoglobulin epidermal growth factor 8, carbohydrate antigen 125 and carcinoembryonic antigen in patients with breast cancer. Chinese Gen Clin. 2016;32(11):1020–2.

Burstein HJ., Bellon JR., Galper S., Lu HM., Kuter I., Taghian AG., et al. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006;64(2):496–504. doi:10.1016/j.ijrobp.2005.07.975.